Anika Resumes Global Distribution of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX
December 04 2018 - 4:05PM
Business Wire
Company Expands HYALOFAST Commercial Reach in
Asia, the Middle East and Latin America
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated
orthopedic and regenerative medicines company specializing in
therapeutics based on its proprietary hyaluronic acid ("HA")
technology, today announced that it has resumed global distribution
of its solid HA-based treatments, including HYALOFAST, a
biodegradable, HA-based cartilage repair scaffold, after a
voluntary, non-safety related recall in the second quarter of 2018.
Following recent regulatory approvals in Thailand, the United Arab
Emirates and Colombia, HYALOFAST has a commercial footprint in
approximately 15 countries.
“Since May, our quality and operations teams have worked
tirelessly to get us back on line to resume shipments before the
end of this year, and we’ve delivered on that promise,” said Joseph
Darling, President and CEO, Anika Therapeutics. “We are excited to
bring the benefits of these products back to the patients who need
them. HYALOFAST, in particular, is a truly remarkable advancement
in the treatment of cartilage defects due to its flexible
minimally-invasive means of application and adaptive fit to
individual patient needs. These features have led to an
overwhelmingly positive physician response to the therapy and
illustrate its significant advantages over traditional
microfracture surgeries and conventional scaffolds.”
HYALOFAST is a non-woven, single-step, off-the-shelf,
biodegradable HA-based scaffold for hyaline-like cartilage
regeneration to treat cartilage injuries and defects. To date, the
Company has seen HYALOFAST used to treat more than 15,000 patients
internationally and has compiled strong eight-year patient
follow-up data. HYALOFAST is pending regulatory submission in the
United States and its FastTRACK Phase III trial is currently
enrolling patients across the U.S. and Europe.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global,
integrated orthopedic medicines company based in Bedford,
Massachusetts. Anika is committed to improving the lives of
patients with degenerative orthopedic diseases and traumatic
conditions with clinically meaningful therapies along the continuum
of care, from palliative pain management to regenerative tissue
repair. The Company has over two decades of global expertise
developing, manufacturing, and commercializing more than 20
products based on its proprietary hyaluronic acid (HA)
technology. Anika's orthopedic medicine portfolio
includes ORTHOVISC®, MONOVISC®,
and CINGAL®, which alleviate pain and restore
joint function by replenishing depleted HA,
and HYALOFAST, a solid HA-based scaffold to aid
cartilage repair and regeneration. For more information about
Anika, please visit www.anikatherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181204006033/en/
For Investor Inquiries:Anika Therapeutics, Inc.Sylvia Cheung,
781-457-9000Chief Financial OfficerFor Media Inquiries:W2O
GroupSonal Vasudev, 917-523-1418sonal@w2ogroup.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2023 to Apr 2024